|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
��ͻϸ�� |
|
��ͷ״������,�� |
| ��������������� | |
|
���� |
|
���Ӣ |
| PubMed | |
|
Article by ���� |
|
Article by ���Ӣ |
�ڷ���HPV��Ⱦ����ͻ״ϸ����Ӧ���о�
����1, ���Ӣ2
1. �ӱ�ҽ�ƴ�ѧ��һҽԺƤ���� ʯ��ׯ 050031;
2. �ӱ�ҽ�ƴ�ѧ���������
����ͷ��������Ⱦ��Ϊһ��������ز��������ܵ����ǵ�����,���������״���������൱��Ĺ�ϵ����ͻ״ϸ���ڻ������߷�Ӧ�еĵ�λ�ѵõ�ȷ����������Ӧ����ͻ״ϸ����������ͷ��������Ⱦ���о���������,��ͻ״ϸ���IJ����п���Ϊ����ͷ��������Ⱦ�ķ����ṩ��Ч������
1. �ӱ�ҽ�ƴ�ѧ��һҽԺƤ���� ʯ��ׯ 050031;
2. �ӱ�ҽ�ƴ�ѧ���������
1. �ӱ�ҽ�ƴ�ѧ��һҽԺƤ���� ʯ��ׯ 050031;
2. �ӱ�ҽ�ƴ�ѧ���������
[2] Inaba K, Inaba M, Naito M,et al. Dendritic cell progenitors phagocyrose particulates, inluding bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med, 1993,178:479-488.
[3] Sallusto F, Cella M, Danieli C, et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med, 1995,182:389-400.
[4] Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med, 1994,179:1109-1118.
[5] Coleman N, Birley HD, Renton AM,et al. Immunological events in regressing genital warts. Am J Clin Pathol, 1994,102:768-774.
[6] Leigh IM, Glover MT. Cutaneous warts and tunours in immunosuppressed patients. J R Soc Med, 1995,88:61-62.
[7] Mommaas AM, Mulder AA, Jordens R, et al. Human epidermal Langerhans cells lack functional mannose receptors and a fully developed endosomal/lysosomal compartment for loading of HLA class IImolecules. Eur J lmmunol, 1999,29:571-580.
[8] Svensson M, Wick MJ. Classical MHC class I peptide presentation of a bacterial fusion protein by bone marrow-derived dendritic cells. Eur J Immunol, 1999,29:180-188.
[9] Frazer IH, Thomas R, Zhou J,et al. Potential strategies utilised by papillomavirus to evade host immunity, Immunol Rev, 1999,168: 131-142.
[10] Fausch SC, Da Silva DM, Rudolf MP, et al. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol,2002,169:3242-3249.
[11] Arrese J, Paquet P, Claessens N,et al. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol, 2001,28:131-134.
[12] Connor JP, Ferrer K, Kane JP,et al. Evaluation of Langerhans' cells in the cervical epithelium of women with cervical intraepithelial neoplasia. Gynecol Oncol, 1999, 75:130-135.
[13] McHugh RS, Ahmed SN, Wang YC, et al. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci U S A, 1995,92:8059-8063.
[14] Larsen CP, Ritchie SC, Pearson TC,et al. Functional expression of the costimulatory molecule, BT/BB1, on murine dendritic cell populations. J Exp Med, 1992,176:1215-1220.
[15] Doan T, Chambers M, Street M,et al. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Virology, 1998, 244:352-364.
[16] Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola virus infection. Nat Med, 1998, 4:37-42.
[17] Tuting T, DeLco AB, Lotze MT, et al. Genetically modified bone marrow-derived dendritic cells expressing lumor-associated viral or"self" antigens induce antitumor immunity in vivo. Eur J Immunol,1997,27:2702-2707.
[18] Tillman BW, Hayes TL, DeGruijl TD,et al. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against hunan papillomavirus 16-induced tumor cells in a murine model. Cancer Res, 2000,60:5456-5463.
[19] Cheng WF, Hung CF, Hsu KF,et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomaL/lysosomal compartments. Hum Gene Ther, 2001,12:235-252.
[20] Indrova M, Bubenik J, Simova J,et al. Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro prining of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide. Int J Mol Med, 2001,7:97-100.
[21] De Bruijn ML, Schuurhuis DH, Vierboom MP, et al. Inmunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res, 1998,58:724-731.
[22] Kaufmann AM, Nieland J, Schinz M, et al. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer, 2001,92:285-293.